Evidence map›Paper›PMID 26951845›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2016

Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers.

Jian-Min Yuan, Irina Stepanov, Sharon E Murphy, Renwei Wang, Sharon Allen, Joni Jensen, Lori Strayer, Jennifer Adams-Haduch, Pramod Upadhyaya, Chap Le and 5 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00691132 (Randomized Trial of PEITC as a Modifier of NNK Metabolism in Smokers), which is not on this map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00691132 phase2completednot on this map

Randomized Trial of PEITC as a Modifier of NNK Metabolism in Smokers

TypeinterventionalSponsorUniversity of MinnesotaRan2009 to 2013Enrolled107ConditionsLung Cancer, Tobacco Use DisorderArmsphenethyl isothiocyanate, placebo
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 84 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Effects of 2-Phenethyl Isothiocyanate on Metabolism of 1,3-Butadiene in Smokers.Cancer prevention research (Philadelphia, Pa.) · 2020
    Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. The Anti-AGEing and RAGEing Potential of Isothiocyanates.Molecules (Basel, Switzerland) · 2024
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Gain of Function (GOF) Mutant p53 in Cancer-Current Therapeutic Approaches.International journal of molecular sciences · 2022
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Jian-Min YuanDivision of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.
Irina StepanovMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Sharon E MurphyMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. Department of Biochemistry, Molecular Biology and BioPhysics, University of Minnesota, Minneapolis, Minnesota.
Renwei WangDivision of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Sharon AllenMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Joni JensenMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Lori StrayerMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Jennifer Adams-HaduchDivision of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Pramod UpadhyayaMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Chap LeMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Mindy S KurzerDepartment of Food Science and Nutrition, University of Minnesota, St. Paul, Minnesota.
Heather H NelsonMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota.
Mimi C YuDepartment of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California.
Dorothy HatsukamiMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Stephen S HechtMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. hecht002@umn.edu.
University of Pittsburgh · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Randomized trial of PEITC as a modifier of NNK metabolism in smokersR01CA122244 · NCI · UNIVERSITY OF MINNESOTA · PI HATSUKAMI, DOROTHY K, YUAN, JIAN-MIN · 2008 to 2012
$2.9M
NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA122244
6 · The paper itself

Abstract

2-Phenethyl isothiocyanate (PEITC), a natural product found as a conjugate in watercress and other cruciferous vegetables, is an inhibitor of the metabolic activation and lung carcinogenicity of the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in F344 rats and A/J mice. We carried out a clinical trial to determine whether PEITC also inhibits the metabolic activation of NNK in smokers. Cigarette smokers were recruited and asked to smoke cigarettes containing deuterium-labeled [pyridine-D4]NNK for an acclimation period of at least 1 week. Then subjects were randomly assigned to one of two arms: PEITC followed by placebo, or placebo followed by PEITC. During the 1-week treatment period, each subject took PEITC (10 mg in 1 mL of olive oil, 4 times per day). There was a 1-week washout period between the PEITC and placebo periods. The NNK metabolic activation ratio [pyridine-D4]hydroxy acid/total [pyridine-D4]NNAL was measured in urine samples to test the hypothesis that PEITC treatment modified NNK metabolism. Eighty-two smokers completed the study and were included in the analysis. Overall, the NNK metabolic activation ratio was reduced by 7.7% with PEITC treatment (P = 0.023). The results of this trial, while modest in effect size, provide a basis for further investigation of PEITC as an inhibitor of lung carcinogenesis by NNK in smokers. Cancer Prev Res; 9(5); 396-405. ©2016 AACR.

Indexed as

Activation, MetabolicAdultAnticarcinogenic AgentsCarcinogensCross-Over StudiesDouble-Blind MethodFemaleHumansIsothiocyanatesMaleMiddle AgedNitrosaminesSmoking4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneAnticarcinogenic AgentsCarcinogensIsothiocyanatesNitrosaminesphenethyl isothiocyanate

Identifiers

PMID26951845
PMCPMC4854759
OpenAlexW2296733663

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.